Overexpression of oncogenes or loss of tumour suppressors can transform a normal cell to a cancerous one, resulting in uncontrolled regulation of intracellular signaling pathways and immunity to stresses, which both pose therapeutic challenges.
Introduction
The efficiency of chemotherapeutic protocols depends on the extent to which the drug can abate and eradicate cancerous cells without destroying normal healthy cells.
Successful chemotherapy thus depends on the selective targeting of tumour cells [1, 2] . Indeed, a paradigm shift in chemotherapeutic research has occurred over the past decade, with the focus moving from the discovery of new cytotoxic drugs to the development of target-specific protocols, aided by nanotechnology, for the selective treatment of cancer [3] . Such specific targeting of cancer cells and the subsequent administration of a drug to a selected site can potentially enhance the chemotherapeutic prognosis and reduce unwanted side effects, as illustrated in the cartoon in Figure 1 (see http://www.cancer.gov/ for a detailed description of chemotherapy side-effects). In turn, the extent of selectivity of a chemotherapeutic drug towards the diseased cell is directly correlated with improved quality of life and survival rate of patients.
In 1906, Paul Ehrlich coined the term "magic bullet" to describe the ideal therapeutic reagent, possessing excellent targeting ability with super specificity [4] . Despite the many thousands of research articles that have since been published on drug targeting, this vision has remained an elusive goal in clinical practice. Although the available chemotherapeutic library has achieved moderate size and includes drugs that can target the intra-cellular signalling process, the cytoskeleton, DNA, the cell cycle and more, most drugs cannot differentiate between normal and cancer cells and, as a result, millions of patients are dying even after medication [5] . Moreover, during chemotherapy, patients often suffer from an increasing range of side effects ranging from infertility and memory loss to heart attack [6] .
Nanoscale research has taken up this challenge. By improving site specificity, nanoscale technology offers the possibility of exceptional improvements in earlystage diagnosis and therapeutics, and also the potential for circumventing multi-drug resistance (MDR) [7, 8] .
Nanoscale materials are currently being investigated to improve their specificity towards cancer cells and towards sub-cellular compartments in order to reduce systemic toxicity. A substantial number of such materials have received clinical approval for reduction of drug toxicity, but have yet to be translated into therapies, due to concern about their eventual fate. Current efforts are therefore aimed at integrating specific targeting, real-time monitoring, biocompatibility, and excellent pharmacokinetic profiles [9, 10] . The short-and long-term effects of such nanoscale materials are still unknown, but nanoscale research is presenting some tantalising questions. Might it be possible in the future for the pathologist to trace and diagnose the very first transformed cell that might lead to cancer? Could a doctor track down individual cancer cells and remove them from the circulation? Would it be possible to specifically instruct a cancer cell to self-destruct? Can a nanoscale material be designed to sense when, where and to what extent a drug should be released to avoid side effects and MDR?
Each of these functionalities could bring further complexity to the design [11] . Here, we focus on the trade-off between achieving such multifunctional "magic bullets" and specificity at the nanoscale in the effort to improve early stage detection and reduce collateral damage as side effects, central issues in the field of nanotechnology in cancer treatment.
Nanoscale diagnosis: molecular and cellular selection
Cancer is a heterogeneous disease that rapidly progresses to an uncontrollable stage after onset [12, 13] . Thus, the survival and quality of life of patients depend directly on the stage at which the cancer has been detected; the most important factor in cancer management therefore is the detection of cancer cells at an early stage. Conventional detection systems that are regularly used by pathologists include the vacuum-assisted Mammotome ® Breast Biopsy System for breast cancer, Papanicolau test to detect potentially pre-cancerous and cancerous processes for cervical cancer, Hemoccult Test for colorectal cancer, sputum cytology for lung cancer, digital rectal examination and prostate-specific antigen (PSA) level for prostate cancer, combined with imaging (endoscopy, X-ray, CT, MRI and ultrasound). However, none of these are very sensitive for an earlystage detection [12, 14] . Nanotechnology-based approaches offer the possibility of reliably detecting and amplifying weak signals arising from a very early-stage transforming cell.
The detection of molecular biomarkers expressed during cancer onset is now an intensely researched area of nanotechnology and Tables 1 and 2 illustrate some recent developments. One such advanced example are 'Nanobiochips' that have been developed as integrated biosensors using quantum dots (QDs) that can potentially be used as multiplexed tools for quantitation of cancer markers such as carcinoembryonic antigen (CEA), cancer antigen (CA) 125, and Her-2/Neu (C-erbB-2). They offer very high specificity in serum and saliva and may also be integrated with nanofluidic arrays to facilitate detection of sub cellular constituents [15, 16] 
Early stage in vivo selection
In vivo selection: In the ideal case, the transforming event would be probed by non-invasive means for the early-stage detection of cancer onset. An example of this type of approach was reported by Harisinghani et al. [17] . The authors used Ferumoxtran-10 (Combidex; Advanced Magnetics Inc, Cambridge, MA, USA), an ultrasmall, superparamagnetic, biodegradable iron oxide particle that is covered with a low-molecular-weight dextran as lymphotropic paramagnetic nanoparticles that facilitate detection of clinically occult lymph-node metastases by enhancing MRI contrast in patients with prostate cancer. Such metastases are undetectable by any other non-invasive approach. Probing the surrounding microenvironment by nanotechnology can provide further information on the onset and status of the early-stage disease [18] . Sustained angiogenesis is one of the important signatures of disease onset. The imaging of such events with very low amounts of epitope targeted by nanoparticles could be an important step for early-stage detection of cancer [19] .
Platform selection:
Currently, there is no suitable platform to detect the presence of cancer biomarkers at ultralow concentrations, but promising results are emerging from nanotechnology-based approaches for the amplification and detection of such ultra-low signatures. Nanoscale surface patterning is one such example, where carbon nanotube patterning has been used for the detection of carcinoembryonic antigen (CEA), a glycosyl phosphatidyl inositol (GPI) cell surface-anchored glycoprotein involved during foetal development. The production of CEA stops before birth and its reappearance serves as an important cancer biomarker [20] .
Surface-Enhanced Laser Desorption / Ionisation Time-of-Flight Mass Spectrometry (SELDI-TOF-MS), is a promising MS platform for the detection of trace amounts of peptides and small molecules at the specific tumour microenvironment, which is now under investigation in combination with nanomaterials for early-stage detection of cancer [21, 22] . Nanotechnology-based multiplex platforms are also emerging as future diagnostic approaches for sensitive and reliable detection. One of the best examples is the 'bio-barcode' developed by Mirkin, which consists of twocomponent oligonucleotide-modified nanoparticle probes [23] , which can detect zeptomolar concentrations. Such nanotechnology-based platforms thus show considerable promise for probing early cell transformations by both in vivo and ex vivo measurement [24] .
Nanocarriers in cancer cell selection
Nanocarriers also offer a new mode of chemotherapeutic drug delivery. The unique physicochemical properties of nanomaterials can be exploited for developing such systems. Examples include: (i) tunable surface charge (+ve) to promote electrostatic interaction with the comparatively negatively charged cancer cell surface (compared to normal cells) in order to stimulate endocytosis; (ii) tunable hydrophilic surfaces with stealth properties to prevent clearance by the reticulo-endothelial systems (RES) to prolong circulation times, thus avoiding opsonisation, the process by which foreign particles are altered by opsonins so as to become more readily and efficiently engulfed by phagocytes; and (iii) modification on the surface of nanoparticles to target specifically cancer cell membranes, the tumour microenvironment, or the sub cellular compartment. As a result of these approaches, nanocarriers can deliver high concentrations of drug to a selected site with reduced systemic cytotoxicity. One such example is described by Han et al ., where they demonstrate that the antitumuor efficacy of nanoparticles carrying the anticancer drug camptothecin, can be enhanced by incorporating on average a single antibody Herceptin [25] . 
Nanoscale cell selection

Passive selection:
The biology of tumour growth and progression is exploited for passive selection by nanoparticle systems. Cancer cells have a faster proliferation rate than the surrounding normal cells and thus monopolise nutrients while generating more waste products, hence exerting stress on healthy cells. Gradually, cancer cells replace healthy cells and form a small cluster of rapidly proliferating cells, until the tumour reaches the diffusion limit size of around 2mm 3 [26] . At this point the normal cells cannot compete for an adequate supply of amino acids, nutrients, oxygen, and glucose, and are unable to manage the excreted waste. However, cancer cells survive in this limiting environment by inducing angiogenesis, overcoming the stress by increasing the surrounding vasculature. In such cases, there are always abnormalities in the basement membrane of the vessels due to defective angiogenesis, resulting in leaky vessels (gap size ranges from the nanometre to micrometer scale). Also, the lymphatic drainage network is abnormal and the asymmetric interstitial pressure (interstitium is the collagen-rich matrix that surrounds cancer cells and separates them from the vasculature) in the tumour inner core prevents normal diffusion of molecules [27] .
Nanotechnology-based approaches exploit these opportunities to target tumour cells.
Nanomaterials can escape through the leaky vasculature and can become trapped within the tumour due to the dysfunctional lymphatic drainage system. This phenomenon in fact generates an enhanced permeation and retention (EPR) effect for the nanomaterials in the tumor compared to conventional drug molecules, while avoiding normal healthy tissue, which has non-leaky vessels and a proper lymphatic drainage system [18] . Another mode of passive selection depends on the tunable surface charge of nanoparticles. The surface of tumour endothelial cells contains more negative charges due to the presence of sialic acids and overexpressed phospholipids, and these can be selected by positively charged nanoparticles due to electrostatic interactions [28] .
Active selection: Surface-active biomolecules can bind either non-internalising target molecules or endocytosis-active molecules. In the former case, the nanoparticle is not engulfed, but resides on the surface of vascular endothelial cells; the drug-loaded nanoparticles can then release the drug with higher local concentration near the target site. In the latter case, a broad range of chemotherapeutic agents can be delivered including siRNAs and DNA binding drugs etc. Table 4 
Systemic selection
Systemic selection targets uncontrolled replication of cancer cells, angiogenesis during tumour growth, and metastasis. These events are not independent and may occur simultaneously, depending on the stage of the cancer. This heterogeneity of cancer is also being tackled by the design of multifunctional nanoscale systems for anticancer therapy.
Selection through uncontrolled proliferation
Cell cycle regulation is highly conserved to ensure normal growth and the proper architecture of tissues and organs. Damage to this regulation can induce an uncontrolled cell growth [29] , which leads to the emergence of a more efficient proliferating machinery that replicates the cell without control. Such cells over express altered surface molecules, which can become targets for nanoparticle-based systems equipped with antibodies (against surface peptides or glycoproteins), aptamers (against surface antigens), or specific ligands (for receptors) [30] . Cancer cell surface host molecules that are regularly selected for study are: (i) folate receptor; (ii) transferrin receptors; and (iii) endothelial receptors. [33] . Herceptin, comprising a monoclonal antibody that targets HER, provides one example. It has been used in nanoconjugated systems for the selection of cancer cells expressing HER [34] .
Nanomaterials: intrinsic cell selection
Recent reports describe nanomaterials without any targeting molecules on the surface, which can nevertheless be selectively taken up and produce a cell-specific response.
The first report in this direction was from Patra et al., who showed that citrate-capped gold nanoparticles can selectively target human lung epithelial cells (A549), without interacting with BHK21 kidney cells and HepG2 liver cells, as illustrated in Figure   3A [35]. This report first coined the term 'cell selective' nanoparticles and is now supported by a large number of new reports along the same lines [36] , although the exact molecular mechanism is still unknown. The asymmetric distribution of the nanoparticles just outside the nucleus suggests the possibility of sub-cellular selection, as illustrated in Figure 3B and C. Later, Fraga et al. extensively investigated HepG2 cells [37] and also found that citrate and 1-mercaptoundecanoic acid (11-MUA) coated gold nanoparticles are taken up by the human liver cancer cells with indicative DNA damage.
The intrinsic selection by nanoparticles is likely dependent not only on the composition of the material itself, but also its size, shape, charge and surface conjugations. Thus, different cell types may react to different aspects of the particle.
For example, Sohaebuddin et al., using a set of multi-wall carbon nanotubes, silicon oxide and titanium oxide nanoparticles, showed that the mechanism of response to the particles, even using the same nanomaterial, varied from one cell type to the next [38] . In addition, they have found that the response is variable between cell types and they explained such selection due to the physiological function of the cell types. Patra The geometry of a nanoparticle may also play a role. Jin et al. proposed a quantitative model for endocytosis rate based on nanoparticle geometry. They have shown sizeand geometry-dependent cellular uptake and expulsion of single-walled carbon nanotubes and gold nanoparticles by single particle tracking [42] . Several investigations are ongoing to correlate the intrinsic effect of such nanomaterial properties with cellular function, uptake, transportation and toxicity in vitro and in vivo [43, 44] . Below, we highlight the rationale for these studies and review the unusual interactions of nanomaterials with tissue types to provide a perspective on the long-term implications of these findings.
Tissue specific cell selection
Recent statistics show that one in four deaths are due to cancer. In males, estimated new cases in 2013 for prostate cancer are estimated at 28% and at 14% for lung cancer. Similarly, in females, new cases are estimated at 29% for breast cancer and 14% for lung cancer [5] . Thus, it is reasonable to focus on these cancer types in the search for cellular target selection by nanomaterial systems.
Prostate cancer selection:
The prostate cancer cell surface contains prostate specific membrane antigen (PSMA). This antigen (a trans-membrane glutamate carboxypeptidase II glycoprotein) is widely used for selecting prostate cancer cells [45] . Antibodies and aptamers specific for PSMA are used for diagnostic and therapeutic purposes [46] . In vivo studies show that targeted nanoparticle systems can effectively select prostate cancer cells (LNCaP prostate cancer cells) and inhibit tumour growth compared to non-targeted and bare drug [47] . An alternative involves folate, as discussed in the section above. Similarly,  factors expressed by the prostate cancer cell surface can be used for selection, but this is not restricted to prostate cancer only [48] .
Breast cancer selection:
As discussed previously, one of the most important surface markers overexpressed in breast cancer is HER-2, and Herceptin is commercially used for the successful treatment of metastatic breast cancer [49] . Nanoparticle systems conjugated with HER-2 antibody fragment are being investigated for selective imaging, drug delivery and gene silencing through siRNA [50, 51] . As in the case of prostate cancer, folate-receptor-mediated nanoparticle systems are also being developed. For localised breast cancer selection, another important molecular marker is luteinising hormone-releasing hormone (LHRH) receptor on breast cancer cells. A superparamagnetic iron oxide nanoparticle (SPIONs) based system has been developed for detection of breast cancer metastasis (LHRH-conjugated magnetic iron oxide nanoparticles) [52] . Importantly, the in vivo study showed that the LHRHSPIONs nanoparticle system did not accumulate in the livers of normal mice, suggesting that off-target effects were limited. By contrast, the non-targeted controls accumulated in the liver, making this study one of the best examples of successful selection of specific cancer cells by nanoparticles [52] .
Lung cancer selection:
Although lung cancer is one of the leading causes of death worldwide, there is no established specific selection system developed for its diagnosis and therapy [5] . As a result, conventional chemotherapy and radiation protocols used along with surgical procedures, resulting in extensive side effects and quality poor life [53] . Thus there is a great need to design better therapies. The landmark work of Chen et al. [54] resulted in an aptamer that can specifically select small-cell lung cancer. The in vitro study showed specific cellular selection over different kinds of cancer cells including leukaemia, and liver and even lung adenocarcinoma. The aptamer was conjugated with magnetic nanoparticles for the selective targeting and isolation of small-cell lung cancer cells and later on, detection through fluorescent nanoparticles. This is the first successful example of small-cell lung cancer cell selection, isolation and detection by a nanoparticle system [26, 54] .
Specific selection using nanomaterials
Species-specific selection: The first reported species specificity showed that gold nanoparticles can interact with the human lung epithelial cancer cell line (A549), but not with baby hamster kidney cell line (BHK21) [35] . Such evidence of selectivity was again reported recently using different sizes of copper nanoparticles. The differential behaviour has been observed for mammalian (H4IIE and HepG2) and piscine cell lines (PLHC-1 and RTH-149) [55] . These results may aid in the design of therapies against cancers induced by other species such as oncoviruses. In such cases the nano-aided system might be helpful in differentiating the transformed cells from the host.
Sex-specific selection:
Recent in vivo reports show gold nanoparticles can induce different interactions in males and females and indicate a sex bias in nanoparticle activity. One study showed that gold nanoparticles can induce significant kidney damages in female mice, while inducing liver damage in males [56] . The mechanism is yet to be established, but this effect should be considered when metallic nanoparticles are applied for chemotherapeutic purposes.
Multidrug resistance: cell selection
Development of tumour drug resistance is now considered a major hurdle restricting al. [57] . MDR and possibilities for nano-based approaches to conquer MDR, are illustrated in Figure 4 and discussed below. Table 5 lists nanotechnology-based approaches for overcoming MDR that are currently undergoing clinical trials.
Redressing chemotherapy regimens
Nanotechnology enables the simultaneous presentation of multiple drugs around a central nanoparticle scaffold [58] , allowing clinicians to administer the maximum number of chemotherapeutic drugs at the highest possible dose in the hope that the cancer cell will not be resistant to all the drugs. It is expected that threshold drug concentrations can be reached for effective chemotherapy even after the drug has been pumped out by the multidrug-resistant cancer cell.
Targeting MDR key player P-gp
P-gp is one of the key players in MDR. Direct targeting of P-gp and its depletion using nano-conjugated antibody may improve chemotherapy protocols in two ways. 
Nanoscale cocktail
A combination of different modules in a single nanoparticle system to bypass tumor drug resistance is in a clinical trial. In this example, TOCOSOL, a paclitaxel and vitamin E nanoscale emulsion, is equipped with a P-gp inhibitor TGPS [60] .
.
Next-generation nanodrugs: cell selection
Design of the first generation of nanodrugs sought mainly to increase the bioavailability of drugs at the tumour site and, to some extent, to reduce their side effects. The first nanodrug approved by the FDA was the paclitaxel protein-bound particle Abraxane that was indicated for the first-line treatment of patients with metastatic adenocarcinoma in 2005, and since then the list has expanded as shown in Table 3 . Drug efflux by P-glycoprotein (P-gp) [1] , an MDR1 gene product [2] , or the MDR protein (MRP) can reduce the effective drug dose to sub-threshold levels. MRP cotransports glutathione, which can detoxify a variety of alkylating agents through neutralisation [3] . Nanotechnology offers several different approaches to overcome these challenges. The nanotechnology-based approach can selectively target P-gp to stop drug clearance [I and ii]; the local concentration of the drug can be increased due to the positive enhanced permeability and retention (EPR) effect and the amount of drug delivered by the nanocarrier [iii]; a combinatorial drug delivery system can be used for delivery of multiple drugs simultaneously to avoid clearance of all drug molecules [iv] . In MDR, p53 alters apoptotic signalling molecule Bcl-2 and cell cycle regulatory molecule microtubule-associated protein (MAP)4 [4] . The release of transcription factor E2F regulates drug sensitivity (e.g., methotrexate, and fluorouracil etc) by producing dihydrofolate reductase (DHFR) and thymidylate synthetase (TS). Mutations in topoisomerases (topo) generate resistance to anthracyclines and etoposide, which can be countered by combinatorial therapy with multiple drugs in a single nanoparticle system [iv].
Figure 5: Nano bullet
Multiplex nanoparticles with all the required functionalities for cancer management may be the way to realise the 'magic bullet' proposed 100 years ago by Paul Ehrlich to treat cancer [4] . 
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